Shanghai Labway Clinical Laboratory Co., Ltd. Class A

Shanghai Labway Clinical Laboratory Co., Ltd. Class A

SSZSE:301060
9.17
CNY
-0.33
(-3.47%)
0.13EPS
117.79P/E
4.81BMarket Cap
Shanghai Labway Clinical Laboratory Co., Ltd. Class A
SZSE:301060
(Shenzhen Stock Exchange)

Recent

price

9.17

P/E

ratio

117.79

div

yld

2.24%

ROIC.AI

2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
TTM
CNY
1.31
1.54
6.8
8.49
2.62
2.99
3.27
3.51
5.05
10.48
4.14
4.3
3.77
3.08
Revenue per Share
0.24
0.2
0.92
0.62
0.02
0.21
0.26
0.31
0.58
1.54
-0.35
-0.27
-0.08
0.1
Basic EPS, GAAP
-0.04
-0.28
0.42
-0.8
-0.64
0.32
0.09
0.35
0.3
-0.36
0.37
0.34
0.55
- -
Free Cash Flow per Basic Share
- -
0.02
0.11
0.1
0.08
0.01
0.18
0.1
- -
0.31
0.34
0.02
0.24
0.21
Dividend per Share
0.37
0.57
0.86
1.64
3.06
3.27
3.35
3.47
3.91
5.15
4.45
4.14
3.87
3.89
Book Value per Share
0.37
0.56
0.85
1.56
2.92
3.12
3.23
3.35
3.8
5.07
4.34
4.06
3.79
3.82
Tangible Book Value per Share
352
352
89
95
353
352
352
352
352
401
405
405
384
401
Basic Weighted Avg Shares
463
541
608
805
923
1,053
1,153
1,238
1,778
4,199
1,674
1,742
1,448
1,238
Sales/Revenue/Turnover
24.62
18.44
19.16
11.25
1.73
10.98
11.9
15.11
18.59
27.29
1.55
1.71
2.04
2.24
Operating Margin (%)
5
12
12
19
28
40
48
44
59
78
65
78
79
- -
Depreciation Expense
84
70
82
59
6
73
92
110
204
617
-142
-109
-31
41
Net Income, GAAP
24
21.22
25.16
31.05
462.92
30.02
25.1
17.14
17.74
18.29
- -
- -
246.44
41.8
Effective Tax Rate (%)
18.23
13
13.53
7.3
0.7
6.97
8
8.91
11.46
14.7
-8.46
-6.28
-2.12
3.31
Profit Margin (%)
96
157
229
426
813
900
993
1,020
1,354
1,975
1,504
1,383
1,221
1,241
Working Capital
- -
- -
- -
- -
- -
- -
- -
54
50
46
167
152
109
91
LT Debt
131
201
302
612
1,104
1,181
1,213
1,247
1,640
2,273
1,980
1,820
1,645
1,624
Total Equity
- -
32.59
26.08
10.72
-2.81
6.55
8.72
12.42
17.68
37.38
- -
- -
-1.27
3.09
Return on Invested Capital (%)
- -
40.81
32.39
12.61
-1.5
7.28
7.74
6.82
9.85
23.99
- -
- -
-2.84
1.85
Return on Capital (%)
- -
42.38
32.69
13.34
0.77
6.58
7.91
9.19
14.63
34.03
-7.37
-6.37
-1.92
2.62
Return on Common Equity (%)

Capital Structure

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
ST Debt
59
16
9
LT Borrowings
96
92
87
LT Finance Leases
4
6
4
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
401
401
401
Market Capitalization
3,961
3,272
4,814

Working Capital

CNY

•

in mil. unless spec.
Mar'26
Jun'26
Sep'26
Total Current Assets
1,832
1,647
1,624
Cash, Cash Equivalents & STI
846
761
816
Accounts Receivable, Net
658
588
550
Inventories
281
246
226
Total Current Liabilities
561
407
383
Payables & Accruals
- -
- -
- -
ST Debt
59
16
9
Deferred Revenue
- -
- -
- -

Growth Rates

CNY

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
23.47%
7.9%
-9.64%
Free Cash Flow
-44.31%
-82.24%
50.58%
Net Income, GAAP
104.1%
14%
-71.9%
Sales/Revenue/Turnover
18.47%
21.36%
-16.88%
Total Cash Common Dividend
4,422.33%
8,482.07%
1,160.04%

Quarterly Revenue

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
436
452
432
422
1,742
2025
351
409
- -
346
1,448
2026
287
304
300
- -
- -

Quarterly Earnings Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
0.04
-0.14
-0.17
-0.27
2025
-0.02
0.01
- -
-0.08
-0.08
2026
0.09
0.07
0.02
- -
- -

Quarterly Dividends Per Share

CNY

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.01
0.03
-0.02
- -
0.02
2025
0.02
0.2
- -
0.02
0.24
2026
0.01
0.19
-0.01
- -
- -
Business
Shanghai Labway Clinical Laboratory Co., Ltd. provides third-party medical testing and pathological diagnosis services to medical institutions throughout China, alongside sales of in vitro diagnostic products including instruments, reagents, accessories, and consumables. The company offers comprehensive diagnostic solutions such as blood tests, biochemistry, immunology, microbiological examinations, molecular and cell genetic testing, flow cytometry, drug concentration monitoring, and allergen detection; it also delivers professional technical support to empower hospital laboratories, pathology departments, and central labs in reducing costs, mitigating risks, and enhancing service quality. Founded in 1993 and headquartered in Shanghai at Building 1, Lane 268, Linxin Road, Changning District, the company operates primarily in the diagnostics and research segment of China's healthcare sector, serving hospitals, clinics, and community health centers nationwide with approximately 1,365 employees. In recent developments, Shanghai Labway's basic data platform for AI pathology diagnosis passed acceptance in 2024, advancing its technological capabilities in automated diagnostics. The company reported a projected net loss of CNY 107 million to 157 million for fiscal year 2024, amid challenges including share reductions by major shareholder Heilan Group, which sold shares equivalent to 4.98% of total share capital by December 2024. Leadership changes included the election of Zeng Weixiong as director and chairman in late 2024, alongside board approvals for final cash dividends on A shares payable in June 2025.